Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0000950170-25-040447

Chief Scientific Officer sold 8,500 shares at $10.85 ($92,205)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2025-03-14 Sale 10b5-1 −8,500 $10.85 $92,205 469,142 D
Open-market sales · 8,500 sh · avg $10.85 · $92,205
Loading xslF345X05/ownership.xml…